Champions Oncology, Inc. (CSBR) vs Spero Therapeutics, Inc. (SPRO)
- Champions Oncology, Inc. CSBR 4.70 −1.88%
- Spero Therapeutics, Inc. SPRO 1.10 −2.65%
Champions Oncology, Inc. and Spero Therapeutics, Inc. are both Biotechnology companies. Champions Oncology, Inc. and Spero Therapeutics, Inc. are of similar size ($66.7M and $65.8M). Champions Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.9×. Spero Therapeutics, Inc. grew revenue faster over the last twelve months: 37.2% against 6.65%. Spero Therapeutics, Inc. has the higher net margin (0.00% vs −1.87%) and the higher return on invested capital (0.00% vs −626.2%). Across the 18 metrics below, Spero Therapeutics, Inc. leads on 17 and Champions Oncology, Inc. on 1.
Valuation
Profitability
| Metric | CSBR | SPRO | Biotechnology median |
|---|---|---|---|
| Gross margin | 49.82% | 100.00% | 65.16% |
| Operating margin | (1.68%) | 0.00% | 0.00% |
| Net margin | (1.87%) | 0.00% | 0.00% |
| Free cash flow margin | (10.08%) | 0.00% | 0.00% |
| Return on equity | (28.38%) | 19.17% | (56.36%) |
| Return on assets | (3.56%) | 12.85% | (48.04%) |
| Return on invested capital | (626.23%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack